1410 related articles for article (PubMed ID: 17198079)
1. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
2. Design of clinical trials for therapeutic cancer vaccines development.
Mackiewicz J; Mackiewicz A
Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
[TBL] [Abstract][Full Text] [Related]
3. Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.
Stebbing J; Wood C; Atkins M; Bukowski R; Litwin S; Bower M; Parsa A; Levitsky H
Cancer; 2008 Mar; 112(5):955-61. PubMed ID: 18286505
[TBL] [Abstract][Full Text] [Related]
4. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
5. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
6. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Cell based cancer vaccines: regulatory and commercial development.
Copier J; Ward S; Dalgleish A
Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
[TBL] [Abstract][Full Text] [Related]
9. Potency assays for therapeutic live whole cell cancer vaccines.
Petricciani J; Egan W; Vicari G; Furesz J; Schild G
Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
[TBL] [Abstract][Full Text] [Related]
10. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
André FE; Foulkes MA
Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
[TBL] [Abstract][Full Text] [Related]
11. Gd-Tex Pharmacyclics Inc.
Radford IR
Curr Opin Investig Drugs; 2000 Dec; 1(4):524-8. PubMed ID: 11249709
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging of antiangiogenic agents.
Rehman S; Jayson GC
Oncologist; 2005 Feb; 10(2):92-103. PubMed ID: 15709211
[TBL] [Abstract][Full Text] [Related]
13. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
14. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
15. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
16. Preventive HIV type 1 vaccine clinical trials: a regulatory perspective.
Goldenthal KL; Vaillancourt JM; Geber A; Lucey DR
AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S333-40. PubMed ID: 9814962
[TBL] [Abstract][Full Text] [Related]
17. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
Mosolits S; Nilsson B; Mellstedt H
Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
[TBL] [Abstract][Full Text] [Related]
18. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
20. [Current status and future perspective of cancer vaccine development].
Sasada T; Itoh K
Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
